A new drug could be an effective treatment for some people with low-grade glioma.
According to findings from a research team led by study first-author Ingo Mellinghoff, MD, Chair of MSK’s Department of Neurology: vorasidenib and ivosidenib reduced concentrations of 2-HG by more than 90%, were well-tolerated, and showed encouraging tumor responses amongst 49 patients enrolled in a multisite trial between April 2019 and April 2020. Vorasidenib showed greater brain penetration than ivosidenib. Based on the phase 1 trial results, vorasidenib was advanced to a phase 3 trial.
In the Clinic
Cancer DNA taken from spinal fluid could serve as a liquid biopsy that provides information on brain tumor mutations.
Ingo Mellinghoff is optimistic about the future of brain cancer treatments as the new Chair of MSK’s Department of Neurology.
Physician-scientist Ingo Mellinghoff has been designated the incumbent of the Evnin Family Chair in Neuro-Oncology. Established through the generosity ...
Announcement
The American Association for Cancer Research (AACR), the world's oldest and largest professional organization dedicated to advancing cancer research, held its 2012 annual meeting in Chicago.
In the Lab
Two Memorial Sloan Kettering studies provide new clues about genetic mutations that affect cell behavior and play a role in several types of cancer.
A multicenter team led by Memorial Sloan Kettering neurologist and researcher Ingo K. Mellinghoff has uncovered the relationship between two proteins that play a critical role in glioblastoma, the most common form of brain cancer.
